Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Driver tyrosine kinase gene mutations are increasingly identified in lung cancers.
• BRAF mutations represent potential therapeutic targets, yet data on BRAF-mutated lung carcinomas remain limited.

Purpose of the Study:

• To investigate the frequency and characteristics of BRAF mutations in a large cohort of non-small cell lung cancer (NSCLC) patients.
• To determine the prognostic significance of BRAF mutations in lung cancer.
• To explore the association between BRAF mutations and clinicopathological features.

Main Methods:

• BRAF mutation status was assessed in 2001 surgically resected NSCLC cases.
• High-resolution melting analysis (HRMA) was employed, followed by Sanger sequencing and/or next-generation deep sequencing.
• Histomorphological analysis was performed on BRAF-mutated tumors.

Main Results:

• BRAF mutations were identified in 1.3% (26/2001) of NSCLC cases, predominantly adenocarcinomas.
• Thirteen distinct BRAF genotypes were found, including four novel mutations not previously reported in lung cancer.
• No significant difference in overall survival was observed between patients with wild-type BRAF and those with V600E or non-V600E BRAF mutations.
• Focal clear cell changes were noted in 75% of V600E-mutated tumors.
• V600E mutations were mutually exclusive with EGFR, KRAS, and ALK alterations, while some non-V600E mutations co-occurred with EGFR mutations.

Conclusions:

• BRAF mutations are infrequent in lung cancer within an Asian population.
• BRAF mutation status does not appear to hold prognostic value for lung cancer patients in this cohort.
• Specific BRAF mutations, like V600E, may be associated with distinct histopathological features and co-alteration patterns.